Rodriguez Raul R's Form 4 filing
Rigel Pharmaceuticals Inc (RIGL) · filed Feb 6, 2025
- Accession no.
- 0000905148-25-000411
- Filed
- Feb 6, 2025
- Trade date
- Feb 4-5, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $200.1K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Rodriguez Raul RCIK 0001190279 | Director, Officer (CEO, President) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 4, 2025 | Common Stock | SSaleDisposed | −4,952 | $20.92 | −$103,595.84 | 243,854 | Direct | |
| Feb 5, 2025 | Common Stock | SSaleDisposed | −4,400 | $21.93 | −$96,492 | 239,454 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.